Am J Psychiatry 156:1686-1696, November 1999
© 1999 American Psychiatric Association
Antipsychotic-Induced Weight Gain: A Comprehensive Research Synthesis
David B. Allison, Ph.D.,
Janet L. Mentore, M.S.Ed.,
Moonseong Heo, Ph.D.,
Linda P. Chandler, Ph.D.,
Joseph C. Cappelleri, Ph.D., M.P.H.,
Ming C. Infante, M.S., and
Peter J. Weiden, M.D.
OBJECTIVE: The purpose of this study was to estimate and compare the effects of antipsychotics—both the newer ones and the conventional ones—on body weight. METHOD: A comprehensive literature search identified 81 English- and non-English-language articles that included data on weight change in antipsychotic-treated patients. For each agent, a meta-analysis and random effects metaregression estimated the weight change after 10 weeks of treatment at a standard dose. A comprehensive narrative review was also conducted on all articles that did not yield quantitative information but did yield important qualitative information. RESULTS: Placebo was associated with a mean weight reduction of 0.74 kg. Among conventional agents, mean weight change ranged from a reduction of 0.39 kg with molindone to an increase of 3.19 kg with thioridazine. Among newer antipsychotic agents, mean increases were as follows: clozapine, 4.45 kg; olanzapine, 4.15 kg; sertindole, 2.92 kg; risperidone, 2.10 kg; and ziprasidone, 0.04 kg. Insufficient data were available to evaluate quetiapine at 10 weeks. CONCLUSIONS: Both conventional and newer antipsychotics are associated with weight gain. Among the newer agents, clozapine appears to have the greatest potential to induce weight gain, and ziprasidone the least. The differences among newer agents may affect compliance with medication and health risk.
This article has been cited by other articles:
|
|
|
|
 
C. A. Paciullo
Evaluating the association between clozapine and venous thromboembolism
Am. J. Health Syst. Pharm.,
October 1, 2008;
65(19):
1825 - 1829.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Gentile
Antipsychotic Therapy During Early and Late Pregnancy. A Systematic Review
Schizophr Bull,
September 11, 2008;
(2008)
sbn107v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. L. Jensen
Drug-Induced Hyperphagia: What Can We Learn From Psychiatric Medications?
JPEN J Parenter Enteral Nutr,
September 1, 2008;
32(5):
578 - 581.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Snigdha, C. Thumbi, G. Reynolds, and J. Neill
Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats
J Psychopharmacol,
July 1, 2008;
22(5):
567 - 571.
[Abstract]
[PDF]
|
|
|
|
|
|
|
O. O. Yevtushenko, S. J. Cooper, R. O'Neill, J. K. Doherty, J. V. Woodside, and G. P. Reynolds
Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia
The British Journal of Psychiatry,
June 1, 2008;
192(6):
424 - 428.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Sernyak and R. A. Rosenheck
Antipsychotic Use in the Treatment of Outpatients With Schizophrenia in the VA From Fiscal Years 1999 to 2006
Psychiatr Serv,
May 1, 2008;
59(5):
567 - 569.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Morgan, M. Sargeant, J. Chukwuma, and G. Hughes
Audit of metabolic syndrome in adults prescribed clozapine in community and long-stay in-patient populations
Psychiatr. Bull.,
May 1, 2008;
32(5):
174 - 177.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. G. Ondo, D. Jong, and A. Davis
Comparison of Weight Gain in Treatments for Tourette Syndrome: Tetrabenazine Versus Neuroleptic Drugs
J Child Neurol,
April 1, 2008;
23(4):
435 - 437.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R.-R. Wu, J.-P. Zhao, X.-F. Guo, Y.-Q. He, M.-S. Fang, W.-B. Guo, J.-D. Chen, and L.-H. Li
Metformin Addition Attenuates Olanzapine-Induced Weight Gain in Drug-Naive First-Episode Schizophrenia Patients: A Double-Blind, Placebo-Controlled Study
Am J Psychiatry,
March 1, 2008;
165(3):
352 - 358.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Fell, J. Neill, N. Anjum, L. Peltola, and K. Marshall
Investigation into the influence of a high fat diet on antipsychotic-induced weight gain in female rats
J Psychopharmacol,
March 1, 2008;
22(2):
182 - 186.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R.-R. Wu, J.-P. Zhao, H. Jin, P. Shao, M.-S. Fang, X.-F. Guo, Y.-Q. He, Y.-J. Liu, J.-D. Chen, and L.-H. Li
Lifestyle Intervention and Metformin for Treatment of Antipsychotic-Induced Weight Gain: A Randomized Controlled Trial
JAMA,
January 9, 2008;
299(2):
185 - 193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. S. Fenton and M. R. Chavez
Medication-Induced Weight Gain and Dyslipidemia in Patients With Schizophrenia
Focus,
January 1, 2008;
6(2):
246 - 253.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Weber, M. Colon, and M. Nelson
Pilot Study of a Cognitive Behavioral Group Intervention to Prevent Further Weight Gain in Hispanic Individuals With Schizophrenia
Journal of the American Psychiatric Nurses Association,
January 1, 2008;
13(6):
353 - 359.
[Abstract]
[PDF]
|
|
|
|
|
|
|
O. Sentissi, J. Epelbaum, J.-P. Olie, and M.-F. Poirier
Leptin and Ghrelin Levels in Patients With Schizophrenia During Different Antipsychotics Treatment: A Review
Schizophr Bull,
December 28, 2007;
(2007)
sbm141v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. R. E. Barnes, C. Paton, M.-R. Cavanagh, E. Hancock, D. M. Taylor, and on behalf of the UK Prescribing Observatory for Me
A UK Audit of Screening for the Metabolic Side Effects of Antipsychotics in Community Patients
Schizophr Bull,
November 1, 2007;
33(6):
1397 - 1403.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. S. Jarboe
Considering the Impact on Overall Patient Health When Choosing Antipsychotic Therapy
Journal of the American Psychiatric Nurses Association,
November 1, 2007;
13(5_suppl):
S23 - S28.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. M. McClellan
Olanzapine and Pediatric Bipolar Disorder: Evidence for Efficacy and Safety Concerns
Am J Psychiatry,
October 1, 2007;
164(10):
1462 - 1464.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L Dufresne
Weighing In: Emergent Diabetes Mellitus and Second-Generation Antipsychotics
Ann. Pharmacother.,
October 1, 2007;
41(10):
1725 - 1727.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Vandiver
Health Promotion as Brief Treatment: Strategies for Women with Co-morbid Health and Mental Health Conditions
Brief. Treat. Crisis Interven.,
August 23, 2007;
(2007)
mhm009v2.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Malone, R. M. Carnahan, and E. C. Kutscher
Antipsychotic Medication Use in the Elderly Patient
Journal of Pharmacy Practice,
August 1, 2007;
20(4):
318 - 326.
[Abstract]
[PDF]
|
|
|
|
|
|
|
W.S. Leslie, C.R. Hankey, and M.E.J. Lean
Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review
QJM,
July 1, 2007;
100(7):
395 - 404.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.H. Barnett, P. Mackin, I. Chaudhry, A. Farooqi, R. Gadsby, A. Heald, J. Hill, H. Millar, R. Peveler, A. Rees, et al.
Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia
J Psychopharmacol,
June 1, 2007;
21(4):
357 - 373.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G.D. Cooper, L.C. Pickavance, J.P.H. Wilding, J.A. HarroLd, J.C.G. HaLford, and A.J. Goudie
Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities
J Psychopharmacol,
June 1, 2007;
21(4):
405 - 413.
[Abstract]
[PDF]
|
|
|
|
|
|
|
References
PsychiatryOnline CME,
May 1, 2007;
2007(1):
2 - 2.
[Full Text]
|
|
|
|
|
|
|
J. M. Noel
ASHP Therapeutic Position Statement on the Use of Second-Generation Antipsychotic Medications in the Treatment of Adults with Psychotic Disorders
Am. J. Health Syst. Pharm.,
April 15, 2007;
64(8):
863 - 876.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C.W. Lau, J. D. Douketis, K. M. Morrison, I. M. Hramiak, A. M. Sharma, E. Ur, and for members of the Obesity Canada Clinical Practic
2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]
Can. Med. Assoc. J.,
April 10, 2007;
176(8):
S1 - S13.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C.W. Lau, J. D. Douketis, K. M. Morrison, I. M. Hramiak, A. M. Sharma, E. Ur, and pour les membres du Groupe d'experts d'Obesite Can
Lignes directrices canadiennes de 2006 sur la prise en charge et la prevention de l'obesite chez les adultes et les enfants [sommaire]
Can. Med. Assoc. J.,
April 10, 2007;
176(8):
SF1 - SF14.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W. Goldberg, J. A. Kreyenbuhl, D. R. Medoff, F. B. Dickerson, K. Wohlheiter, L. J. Fang, C. H. Brown, and L. B. Dixon
Quality of Diabetes Care Among Adults With Serious Mental Illness
Psychiatr Serv,
April 1, 2007;
58(4):
536 - 543.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-K. Wu, C.-K. Wang, Y.-M. Bai, C.-Y. Huang, and S.-D. Lee
Outcomes of Obese, Clozapine-Treated Inpatients With Schizophrenia Placed on a Six-Month Diet and Physical Activity Program
Psychiatr Serv,
April 1, 2007;
58(4):
544 - 550.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. F. Kim, A. S. Huang, A. M. Snowman, C. Teuscher, and S. H. Snyder
From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase
PNAS,
February 27, 2007;
104(9):
3456 - 3459.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Y. Meltzer
Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden
PNAS,
February 27, 2007;
104(9):
3019 - 3020.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Archie, J. O. Goldberg, N. Akhtar-Danesh, J. Landeen, L. McColl, and J. McNiven
Psychotic Disorders, Eating Habits, and Physical Activity: Who Is Ready for Lifestyle Changes?
Psychiatr Serv,
February 1, 2007;
58(2):
233 - 239.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Roberts, A. Roalfe, S. Wilson, and H. Lester
Physical health care of patients with schizophrenia in primary care: a comparative study
Fam. Pract.,
February 1, 2007;
24(1):
34 - 40.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Straker, P. A. Shapiro, and P. R. Muskin
Aripiprazole in the Treatment of Delirium
Psychosomatics,
October 1, 2006;
47(5):
385 - 391.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. S. Fenton and M. R. Chavez
Medication-Induced Weight Gain and Dyslipidemia in Patients With Schizophrenia
Am J Psychiatry,
October 1, 2006;
163(10):
1697 - 1704.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. L. Lambert, F. E. Cunningham, D. R. Miller, G. W. Dalack, and K. Hur
Diabetes Risk Associated with Use of Olanzapine, Quetiapine, and Risperidone in Veterans Health Administration Patients with Schizophrenia
Am. J. Epidemiol.,
October 1, 2006;
164(7):
672 - 681.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Lamberti, D. Olson, J. F. Crilly, T. Olivares, G. C. Williams, X. Tu, W. Tang, K. Wiener, S. Dvorin, and M. B. Dietz
Prevalence of the Metabolic Syndrome Among Patients Receiving Clozapine
Am J Psychiatry,
July 1, 2006;
163(7):
1273 - 1276.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. L. Olson, T. Delate, and D. J. Duagn
Monitoring of Patients Given Second-Generation Antipsychotic Agents
Psychiatr Serv,
July 1, 2006;
57(7):
1045 - 1046.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. Kirk, M. Cahir, and G. P. Reynolds
Clozapine, but not haloperidol, increases neuropeptide Y neuronal expression in the rat hypothalamus
J Psychopharmacol,
July 1, 2006;
20(4):
577 - 579.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G. P. Reynolds, M. J. Hill, and S. L. Kirk
The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics.
J Psychopharmacol,
July 1, 2006;
20(4 Suppl):
15 - 18.
[Abstract]
[PDF]
|
|
|
|
|
|
|
W. K. Kroeze and B. L. Roth
Screening the receptorome.
J Psychopharmacol,
July 1, 2006;
20(4 Suppl):
41 - 46.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Z. T. Bloomgarden
Atypical Antipsychotic Agents, Retinopathy, Nephropathy, and Cardiovascular Disease.
Diabetes Care,
June 1, 2006;
29(6):
1439 - 1446.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. I Brixner, Q. Said, P. K Corey-Lisle, A V. Tuomari, G. J L'Italien, W. Stockdale, and G. M Oderda
Naturalistic Impact of Second-Generation Antipsychotics on Weight Gain
Ann. Pharmacother.,
April 1, 2006;
40(4):
626 - 632.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Gianfrancesco, J. Pesa, R.-H. Wang, and H. Nasrallah
Assessment of antipsychotic-related risk of diabetes mellitus in a Medicaid psychosis population: Sensitivity to study design
Am. J. Health Syst. Pharm.,
March 1, 2006;
63(5):
431 - 441.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A Marken and R. W Pies
Emerging Treatments for Bipolar Disorder: Safety and Adverse Effect Profiles
Ann. Pharmacother.,
February 1, 2006;
40(2):
276 - 285.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Micca, V. P. Hoffmann, I. Lipkovich, J. Ahl, R. W. Baker, and T. A. Hardy
Retrospective Analysis of Diabetes Risk in Elderly Patients With Dementia in Olanzapine Clinical Trials
Am J Geriatr Psychiatry,
January 1, 2006;
14(1):
62 - 70.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Hosojima, T. Togo, T. Odawara, K. Hasegawa, S. Miura, Y. Kato, A. Kanai, A. Kase, H. Uchikado, and Y. Hirayasu
Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia
J Psychopharmacol,
January 1, 2006;
20(1):
75 - 79.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. J. Weiden
Switching antipsychotics: an updated review with a focus on quetiapine
J Psychopharmacol,
January 1, 2006;
20(1):
104 - 118.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. Rasmussen, M. J. Benvenga, F. P. Bymaster, D. O. Calligaro, I. R. Cohen, J. F. Falcone, S. K. Hemrick-Luecke, F. M. Martin, N. A. Moore, L. K. Nisenbaum, et al.
Preclinical Pharmacology of FMPD [6-Fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: A Potential Novel Antipsychotic with Lower Histamine H1 Receptor Affinity Than Olanzapine
J. Pharmacol. Exp. Ther.,
December 1, 2005;
315(3):
1265 - 1277.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. B. Zipursky, H. Gu, A. I. Green, D. O. Perkins, M. F. Tohen, J. P. McEvoy, S. M. Strakowski, T. Sharma, R. S. Kahn, R. E. Gur, et al.
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol
The British Journal of Psychiatry,
December 1, 2005;
187(6):
537 - 543.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Malone
Medications Associated with Weight Gain
Ann. Pharmacother.,
December 1, 2005;
39(12):
2046 - 2054.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Best, A. P. Yates, and G. P. Reynolds
Actions of antipsychotic drugs on pancreatic {beta}-cell function: contrasting effects of clozapine and haloperidol
J Psychopharmacol,
November 1, 2005;
19(6):
597 - 601.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. Haddad
Weight change with atypical antipsychotics in the treatment of schizophrenia
J Psychopharmacol,
November 1, 2005;
19(6_suppl):
16 - 27.
[Abstract]
[PDF]
|
|
|
|
